Australian Doctor Australian Doctor 7th September 2018 | Page 7

NEW Trulicity ® (dulaglutide)
is the only GLP-1 RA that
combines proven efficacy
with once-weekly dosing in
a ready-to-use pen
1
Proven HbA 1C
reduction* 1
Once-weekly
dosing 1
Ready-to-use
pen 2
*Trulicity demonstrated unbeaten efficacy in head-to-head
clinical trials against insulin glargine, exenatide BID and
liraglutide, 3–6 with HbA 1C reduction across registration
studies ranging from -0.78% to -1.64% 3,5–8
GLP-1 RA; glucagon-like peptide 1 receptor agonist.
*Hypothetical patient.
NOW PBS
LISTED 9
For more information, speak to your Lilly Sales Representative,
visit lilly.com.au or call 1800 454 559.
PBS Information: Authority Required (STREAMLINED). Type 2 Diabetes. Criteria Apply. Refer to PBS Schedule for full Authority Required Information.
Please refer to Product Information before prescribing. Full Product Information is available on request from Eli Lilly by calling 1800 454 559.
TRULICITY (dulaglutide rch). INDICATIONS – TRULICITY is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. CONTRAINDICATIONS – Hypersensitivity to dulaglutide or any of the excipients.
PRECAUTIONS – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment
with sulfonylurea or prandial insulin may increase risk; congestive heart failure – limited therapeutic experience; carcinogenicity – caused statistically significant dose-related increases in the incidence of thyroid C-cell tumours in rats, however, the human relevance of
these findings is unknown. Use in Pregnancy Category B3. ADVERSE EFFECTS Clinical Trials Experience – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or
insulin), Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity. DOSAGE AND ADMINISTRATION – Dosage: Adults (≥ 18 years): 1.5 mg once weekly, at any time of day, independently of
meals. Elderly Patients (≥65 years): dose adjustment not required. The therapeutic experience in patients ≥75 years is limited. Children and adolescents (<18 years): safety and effectiveness have not been established.
Renal Impairment: no dose adjustment is required in mild or moderate impairment; not recommended in severe renal impairment or end-stage renal disease. Hepatic Impairment: no dose adjustment required.
Administration: subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed.
Date of preparation: 19 October 2017.
References: 1. Trulicity Approved Product Information. 19 October 2017. 2. Matfin G et al. J Diabetes Sci Technol 2015;9:1071–9. 3. Giorgino F et al. Diabetes Care 2015;38(12):2241–9.
4. Dungan KM et al. Lancet 2014;384(9951):1349–57. 5. Wysham C et al. Diabetes Care 2014;37:2159–67. 6. Blonde L et al. Lancet 2015;385(9982):2057–66. 7. Nauck M et al.
Diabetes Care 2014;47(8):2149–58. 8. Umpierrez G et al. Diabetes Care 2014;47(8):2168–76. 9. Pharmaceutical Benefits Scheme (PBS). Available at: www.pbs.gov.au.
TRULICITY ® is a registered trademark of Eli Lilly and Company. Eli Lilly Australia Pty Ltd, 112 Wharf Road, West Ryde NSW 2114. ABN 39 000 233 992. PP-DG-AU-0126. ELB0291. August 2018.